ZY19489, a triaminopyrimidine antimalarial currently in Phase IIb trials, faces low-grade resistance in Plasmodium falciparum due to a novel mutation in the chloroquine resistance transporter PfCRT. T
The antiplasmodial activity, DMPK properties, and efficacy of a series of quinoline-4-carboxamides are described. This series was identified from a phenotypic screen against the blood stage of Plasmod
There is growing interest to apply proteomics to other organisms than just the biomedically relevant and important species such as human, mouse or rat. However, one of the main hurdles for successful
ITDR MS-CETSA was conducted on MMV compounds-treated live parasites and lysate of P. falciparum trophozoites in order to identify potential drug protein targets. MMV compounds: MMV007127, MMV665886.
